Efficiency of chemotherapy GemCap + mitotane as second and subsequent lines of therapy for metastatic adrenocortical cancer

Background. Combination of gemcitabine, metronomic capecitabine and mitotane (GemCap + m) is the most studied regimen in second and subsequent lines of therapy for advanced adrenocortical cancer (ACC). Previously published studies do not give a definitive answer to the question- what plays a key role in realizing the response to treatment: chemotherapy or mitotane in therapeutic concentration.

Aim. Evaluation the efficacy and safety of GemCap + m combination with the standard dosing regimen of capecitabine in patients with metastatic ACC.

Materials and methods. This retrospective single-center clinical study included patients over 18 years of age with histologically confirmed ACC with disease progression after completion of platinum-containing therapy. They received chemotherapy regimen gemcitabine 800 mg/m² for days 1, 8 and capecitabine 1000 mg/m² orally 2 times at days 1–14 of the 21-day cycle with mitotane. we evaluated objective response, stabilization of disease, 6-months disease control rate and median progression-free and overall survival. Radiological assessment according to RECIST 1.1 criteria was carried out every 6–8 weeks of treatment.

Results. The study included 25 patients. mitotane concentration above 14 ng/mL was achieved in 22 (88 %) patients, of which 21 (84 %) reached therapeutic concentration in previous treatment lines. 80 % of patients received treatment as 2^nd line, 20 % as 3^rd and subsequent lines. The objective responses and disease stabilization was observed in 1 (4 %) and 11 (44 %) of patients, respectively. Disease control for at least 6 months rate was 24 %. median progression-free and overall survival were 3.2 months and 12.17 months, respectively. Toxicity grade 3–4 was observed in 28 % of patients. gemcitabine dose reductions due to thrombocytopenia grade 1–2 were required in 2 cases (8 %), no capecitabine reductions were necessary.

Conclusion. This study demonstrates the effectiveness of a new dose regimen of chemotherapy GemCap + m in the second and subsequent lines of therapy for metastatic ACC. The progression of the disease against the background of previous lines of therapy at a therapeutic concentration of mitotane in the majority of patients indicates the effectiveness of the chemotherapeutic component of gemCap in a cohort of patients resistant to platinum and mitotane.

1. Schteingart D.E., Doherty G.M., Gauger P.G. et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 2005;12(3):667–80.

2. Margonis G.A., Kim Y., Prescott J.D. et al. Adrenocortical Carcinoma: Impact of Surgical Margin Status on Long-Term Outcomes. Ann Surg Oncol 2016;23(1):134–41.

3. Fassnacht M., Terzolo M., Allolio B. et al. FIRM-ACT Study Group. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 2012;366(23):2189–97. DOI: 10.1056/NEJMoa1200966

4. Laganà M., Grisanti S., Cosentini D. et al. Efficacy of the EDP-M scheme plus adjunctive surgery in the management of patients with advanced adrenocortical carcinoma: the Brescia experience. Cancers (Basel) 2020;12(4):941. DOI: 10.3390/cancers12040941

5. Zhulikov Y.A., Kovalenko E.I., Bohyan V.Yu. et al. Efficacy of EDP ±, mitotane chemotherapy in the treatment of metastatic adrenocortical carcinoma. Predictive and prognostic factors of efficacy. Malignant Tumours 2021;11(1):37–46.

6. Sperone P., Ferrero A., Daffara F. et al. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr Relat Cancer 2010;17(2):445–53.

7. Henning J.E.K., Deutschbein T., Altieri B. et al. Gemcitabinebased chemotherapy in adrenocortical carcinoma: a multicenter study of efficacy and predictive factors. J Clin Endocrinol Metab 2017;102(11):4323–32.

8. Wortmann S., Quinkler M., Ritter C. et al. Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. Eur J Endocrinol 2010;162(2):349–56. DOI: 10.1530/EJE-09-0804

9. Quinkler M., Hahner S., Wortmann S. et al. Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J Clin Endocrinol Metab 2008;93(6):2057–62. DOI: 10.1210/jc.2007-2564. Erratum in: J Clin Endocrinol Metab 2008;93(8):3230.

10. El Darsa H., El Sayed R., Abdel-Rahman O. What is the real value of metronomic chemotherapy in the treatment of gastrointestinal cancer? Expert Opin Pharmacother 2021;22(17):2297–302. DOI: 10.1080/14656566.2021.1940953